FDA Approves Second Indication for Casgevy Cell-based Gene Therapy

FDA Approves Second Indication for Casgevy Cell-based Gene Therapy     On January 16, the FDA approved Casgevy from Vertex, a cell-based gene therapy, for the treatment of patients 12 years of age and older with transfusion-dependent beta-thalassemia (TDT), an inherited disorder characterized by life-long anemia requiring frequent blood transfusions. To produce Casgevy, patients’ hematopoietic (blood) …

FDA Approves Second Indication for Casgevy Cell-based Gene Therapy Read More »